Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc. (SUPN)
Filing Type: Form 8-K (Current Report)
Date: February 18, 2025
Event: Announcement of topline results from the Phase 2b study of SPN-820 in adults with treatment-resistant depression.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a clinical trial update and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material event reported is the release of topline data for the SPN-820 Phase 2b study. No financial changes or comparisons to prior periods are included in this document.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release (Exhibit 99.1) detailing the study results. Specific commentary on the data is contained within the referenced exhibit and is not detailed in the body of this 8-K.
Risks and Contingencies: No specific risks or contingencies are enumerated in this filing text beyond the inherent uncertainties of clinical development implied by the study announcement.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific efficacy and safety data from the SPN-820 Phase 2b study.
- Verify the statistical significance of the topline results announced.
- Check for any updated timeline for future regulatory filings or Phase 3 trials based on these results.
- Consult the most recent 10-K or 10-Q for current financial position, as this 8-K contains no financial data.